- Home
- ACIC vs AUTL Comparison
ACIC vs AUTL Comparison
Compare ACIC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | AUTL |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.4M | 532.3M |
| IPO Year | 2007 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ACIC | AUTL |
|---|---|---|
| Price | $9.26 | $2.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 271.6K | ★ 3.0M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 39.61 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $335,439,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | $1.00 | $53.96 |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | 13.07 | ★ 496.00 |
| 52 Week Low | $9.33 | $1.18 |
| 52 Week High | $13.06 | $2.58 |
Technical Indicators
Market Signals| Indicator | ACIC | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 32.09 | 69.74 |
| Support Level | N/A | $1.31 |
| Resistance Level | $11.48 | N/A |
| Average True Range (ATR) | 0.39 | 0.22 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 2.23 | 88.66 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.